TransThera Sciences (Nanjing), Inc.
藥捷安康（南京）科技股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 2617)

(1) POLL RESULTS OF THE EXTRAORDINARY GENERAL MEETING HELD ON 18 JUNE 2026; (2) ADOPTION OF THE H SHARE AWARD SCHEME; AND (3) AUTHORIZATION TO THE SCHEME ADMINISTRATOR TO DEAL WITH MATTERS RELATED TO THE H SHARE AWARD SCHEME

The Board is pleased to announce that all proposed resolutions were duly passed by the Shareholders by way of poll at the EGM held on 18 June 2026.

References are made to the notice of the extraordinary general meeting (the "**Notice**") and the circular (the "**Circular**") of TransThera Sciences (Nanjing), Inc. (the "**Company**") both dated 22 May 2026. Unless stated otherwise, capitalised terms used in this announcement shall have the same meanings as those defined in the Circular.

The Board is pleased to announce that all proposed resolutions as set out in the Notice were duly passed by the Shareholders at the EGM by way of poll.

As at the date of the EGM, the total number of issued Shares of the Company was 407,918,633 Shares, of which 312,687,673 Shares were H Shares and 95,230,960 Shares were Unlisted Shares. All Shares entitled the holders to attend the EGM and vote on the resolutions proposed at the EGM.

No Shareholder was required under the Listing Rules to abstain from voting on the proposed resolutions at the EGM. There were no Shares entitling the Shareholders to attend the EGM but abstain from voting in favour of the proposed resolutions at the EGM under Rule 13.40 of the Listing Rules. None of the Shareholders have stated his, her or its intention in the Circular to vote against or to abstain from voting on the resolutions at the EGM.

Tricor Investor Services Limited, the H share registrar of the Company acted as the scrutineer for the vote-taking at the EGM.

All Directors attended the EGM.

The poll results in respect of all proposed resolutions at the EGM are as follows:

<table>
<tr><th colspan="2" rowspan="2">SPECIAL RESOLUTION</th><th colspan="3">Number of votes (%)</th></tr>
<tr><th>FOR</th><th>AGAINST</th><th>ABSTAIN</th></tr>
<tr><td>1.</td><td>In relation to the H Share Award Scheme:

1.1 To consider and approve the H Share Award Scheme;

1.2 To consider and approve the Scheme Mandate Limit; and

1.3 To consider and approve the authorization to the Scheme Administrator to deal with matters related to the H Share Award Scheme.</td><td>241,907,932
(85.297%)</td><td>39,662,972
(13.985%)</td><td>2,036,818
(0.718%)</td></tr>
<tr><th colspan="2" rowspan="2">ORDINARY RESOLUTION</th><th colspan="3">Number of votes (%)</th></tr>
<tr><th>FOR</th><th>AGAINST</th><th>ABSTAIN</th></tr>
<tr><td>2.</td><td>To consider and approve the Service Provider Sublimit.</td><td>253,153,776
(85.857%)</td><td>39,662,972
(13.452%)</td><td>2,036,818
(0.691%)</td></tr>
</table>

As more than two-thirds of the votes were cast in favour of the special resolution numbered 1, such resolution was duly passed as a special resolution.

As a majority of the votes were cast in favour of the ordinary resolution numbered 2, such resolution was duly passed as an ordinary resolution.

ADOPTION OF THE H SHARE AWARD SCHEME AND AUTHORIZATION TO THE SCHEME ADMINISTRATOR

Reference is made to (i) the announcement of the Company dated 7 April 2026 in relation to, among other things, the proposed adoption of the H Share Award Scheme and the proposed authorization to the Scheme Administrator to deal with matters related to the H Share Award Scheme, and (ii) the Circular.

As the special resolution in relation to the H Share Award Scheme, the Scheme Mandate Limit and the authorization to the Scheme Administrator to deal with matters related to the H Share Award Scheme was duly approved by the Shareholders at the EGM, and the ordinary resolution in relation to the Service Provider Sublimit was duly approved by the Shareholders at the EGM, the Company hereby announces that the H Share Award Scheme, the Scheme Mandate Limit and the Service Provider Sublimit have been approved by the Shareholders.

As disclosed in the Circular, the H Share Award Scheme becoming effective is conditional upon, among other things, the Listing Committee granting approval of the listing of, and permission to deal in, the Shares to be allotted and issued pursuant to Awards. Therefore, the Adoption Date is expected to be the date on which such approval is obtained.

The Scheme Administrator is authorized to take all relevant measures and deal with all relevant matters to approve and execute on behalf of the Company such documents as are necessary, appropriate or expedient for the purpose of giving effect and implementation of the H Share Award Scheme and to handle matters related to the H Share Award Scheme.

By Order of the Board
TransThera Sciences (Nanjing), Inc.
藥捷安康（南京）科技股份有限公司
Dr. Frank Wu
Chairman and Chief Executive Officer

Hong Kong, 18 June 2026

As at the date of this announcement, the Board comprises Dr. Frank Wu and Mr. Wu Di as executive Directors; Ms. Jia Zhongxin as a non-executive Director; and Mr. Li Shu Pai, Ms. Chui Hoi Yam and Mr. Feng Weibo as independent non-executive Directors.